Pfizer secured up to $1.5 billion from Blackstone through 2028 to fund development of its experimental obesity drug, berobenatide. The agreement preserves full operational control for Pfizer while providing capital for its clinical pipeline. The partnership helps offset declining revenue from pandemic products and upcoming patent expirations.
